September 1, 2014
Takeda Pharmaceutical announced on August 29 the completion of the post-marketing commitment and submissions of data from a 10-year epidemiology study to regulatory authorities in Japan, the US, and Europe for the type 2 diabetes treatment Actos (pioglitazone) and other...read more